There are 2789 resources available
800P - Tailoring adjuvant treatments in high-risk early stage endometrial cancer: Clinical outcomes of sequential chemoradiation in a real-word scenario
Presenter: Marco de Scordilli
Session: ePoster Display
694P - Methylthioadenosine phosphorylase (MTAP) deletion is more common in sarcomatoid (srcRCC) than in clear cell renal cell carcinoma (ccRCC)
Presenter: Andrea Necchi
Session: ePoster Display
695P - Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
Presenter: Marzia Del Re
Session: ePoster Display
696P - Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)
Presenter: Sara Elena Rebuzzi
Session: ePoster Display
697P - Impact of β-blockers (BB) on outcomes of metastatic renal cell carcinoma (mRCC) patients treated with nivolumab (N)
Presenter: Carolina Alves Costa Silva
Session: ePoster Display
806P - Genomic alteration characteristics and potential drug targets of uterine sarcoma
Presenter: Fengxia Xue
Session: ePoster Display
807P - Multi-centre study of escalated etoposide/cisplatin (Esc-EP) as a novel salvage regimen in advanced/refractory gestational trophoblastic neoplasia
Presenter: James Clark
Session: ePoster Display
808P - Characteristics and outcomes of women with adenocarcinoma versus squamous cell carcinoma of the vulva: A Japanese Gynecologic Oncology Group study
Presenter: Shin Nishio
Session: ePoster Display
699P - Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
Presenter: Jonathan Rosenberg
Session: ePoster Display
700P - Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
Presenter: Yohann Loriot
Session: ePoster Display